منابع مشابه
Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review)
The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. On the basis of Class I evidence, natalizumab has been demonstrated to reduce measures of disease activity and to improve measures of disease severity in patients with relapsingremitting (RR) MS (Level A). The relative efficacy of natalizumab compared to current diseasemodifying thera...
متن کاملEvaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
BACKGROUND Patients with multiple sclerosis (MS) or Crohn's disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the potential benefits and potential risks of exposure when considering treatment options. This study was undertaken to evaluate pregnancy outcom...
متن کاملCost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
BACKGROUND Natalizumab (Tysabri) is a new disease-modifying therapy that has been shown to be clinically effective in patients with relapsing-remitting multiple sclerosis (RRMS) and has been licensed for use in patients with highly active RRMS (HARRMS). These patients are those who experience higher relapse rates and faster disability progression than the general RRMS population. OBJECTIVES T...
متن کاملThe comeback kid: TYSABRI now FDA approved for Crohn disease.
The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 3 March 2008 825 The comeback kid: TYSABRI now FDA approved for Crohn disease The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to severely active Crohn disease (CD) who do not respond to, or do not tolerate, conventional therapies for CD and inh...
متن کاملNatalizumab and immune cells.
U NDERSTANDING THE MECHANISMS UNDERlying the unfortunate occurrence of progressive multifocal leukoencephalopathy (PML), a disease caused by reactivation of the JC polyomavirus, in a small subset of patients during treatment of autoimmune disease with natalizumab is important at several levels. The most important and immediate outcome would be a more complete appreciation of the risk of PML, no...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Neuroradiology
سال: 2010
ISSN: 0195-6108,1936-959X
DOI: 10.3174/ajnr.a2226